Literature DB >> 26058752

Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.

Wei Xiao1, Zhiyong Gao1, Yixing Duan1, Wuxiong Yuan1, Yang Ke1.   

Abstract

Metastasis seriously affects the clinical outcome of renal cell carcinoma patients. Despite the approval of several targeted therapies that have led to an improvement in the progression-free survival rate for these patients, advanced and metastatic renal cell carcinoma remains difficult to treat. Recently, microRNAs have been found to play a critical role in the metastatic dissemination of renal cell carcinoma cells. In the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments. In addition, the results were confirmed in renal carcinoma cell lines. miR-19a expression in the cell lines derived from a metastatic site was higher than that in cell lines derived from a primary site. By gain- and loss-of-function experiments, we found that miR-19a acted as an oncogenic miRNA regulating renal cancer cell proliferation, migration and invasion by directly targeting PIK3CA. Furthermore, we also explored the downstream molecules of miR-19a/PIK3CA signaling. We found that Notch signaling was induced by upregulation of miR-19a, and inactivation of Notch signaling attenuated the cell proliferation, migration and invasion promoted by miR-19a. Thus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26058752     DOI: 10.3892/or.2015.4041

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Alpha Protein Kinase 2 Promotes Esophageal Cancer via Integrin Alpha 11.

Authors:  Julaiti Ainiwaer; Liwei Zhang; Maidiniyeti Niyazi; Edris Awut; Shutao Zheng; Ilyar Sheyhidin; JiangHong Dai
Journal:  Biomed Res Int       Date:  2022-06-29       Impact factor: 3.246

2.  Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice.

Authors:  Elinn Johansson; Birgitte Rönö; Martin Johansson; David Lindgren; Christina Möller; Håkan Axelson; Emma M K Smith
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

3.  MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2.

Authors:  Fang Ma; Zhiyuan Wang; Jingjing Wang; Xianling Liu; Chunhong Hu
Journal:  Exp Ther Med       Date:  2017-06-23       Impact factor: 2.447

4.  miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1.

Authors:  Yanqing Liu; Rui Liu; Fei Yang; Rongjie Cheng; Xiaorui Chen; Shufang Cui; Yuanyuan Gu; Wu Sun; Chaoying You; Zhijian Liu; Feng Sun; Yanbo Wang; Zheng Fu; Chao Ye; Chenyu Zhang; Jing Li; Xi Chen
Journal:  Mol Cancer       Date:  2017-03-04       Impact factor: 27.401

5.  miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis.

Authors:  Zhi-Fei Jing; Jian-Bin Bi; Ze-Liang Li; Xian-Kui Liu; Jun Li; Yu-Yan Zhu; Xiao-Tong Zhang; Zhe Zhang; Zhen-Hua Li; Chui-Ze Kong
Journal:  Onco Targets Ther       Date:  2019-04-10       Impact factor: 4.147

6.  miR-133b Downregulation Reduces Vulnerable Plaque Formation in Mice with AS through Inhibiting Macrophage Immune Responses.

Authors:  Cheng-Gen Zheng; Bing-Yu Chen; Ren-Hua Sun; Xiao-Zhou Mou; Fang Han; Qian Li; Hai-Jun Huang; Jing-Quan Liu; Yue-Xing Tu
Journal:  Mol Ther Nucleic Acids       Date:  2019-05-02

7.  Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.

Authors:  Jiang-Hui Zeng; Wei Lu; Liang Liang; Gang Chen; Hui-Hua Lan; Xiu-Yun Liang; Xu Zhu
Journal:  J Transl Med       Date:  2019-08-23       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.